Computers in Biology and Medicine, Journal Year: 2024, Volume and Issue: 185, P. 109497 - 109497
Published: Dec. 13, 2024
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7743 - 7743
Published: July 15, 2024
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer using autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma (MM) have been approved by the Food Drug Administration (FDA). Significant barriers to effectiveness of include cytokine release syndrome (CRS), neurotoxicity in case Allogeneic Stem Cell Transplantation (Allo-SCT) graft-versus-host-disease (GVHD), escape, modest antitumor activity, restricted trafficking, limited persistence, immunosuppressive microenvironment, senescence exhaustion CAR-Ts. Furthermore, cancer drug resistance remains major problem clinical practice. therapy, combination with checkpoint blockades bispecific engagers (BiTEs) other drugs, appears be an appealing strategy. Many these agents shown impressive results, combining efficacy tolerability. Biomarkers like extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor (ctDNA) miRNAs may play important role toxicity, relapse assessment, prediction, can implicated applications establishing safe efficacious personalized medicine. However, further research required fully comprehend particular side effects immunomodulation, ascertain best order this medication conventional chemotherapy targeted therapies, find reliable predictive biomarkers.
Language: Английский
Citations
8
Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)
Published: May 25, 2024
Abstract Hematological malignancies (HMs) encompass a diverse group of blood neoplasms with significant morbidity and mortality. Immunotherapy has emerged as validated crucial treatment modality for patients HMs. Despite notable advancements having been made in understanding implementing immunotherapy HMs over the past decade, several challenges persist. These include immune-related adverse effects, precise biodistribution elimination therapeutic antigens vivo, immune tolerance tumors, evasion by tumor cells within microenvironment (TME). Nanotechnology, its capacity to manipulate material properties at nanometer scale, potential tackle these obstacles revolutionize outcomes improving various aspects such drug targeting stability. The convergence nanotechnology given rise nano-immunotherapy, specialized branch anti-tumor therapy. Nanotechnology found applications chimeric antigen receptor T cell (CAR-T) therapy, cancer vaccines, checkpoint inhibitors, other immunotherapeutic strategies In this review, we delineate recent developments discuss current field nano-immunotherapy HMs, offering novel insights into nanotechnology-based approaches diseases.
Language: Английский
Citations
7
International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 294, P. 139515 - 139515
Published: Jan. 5, 2025
Language: Английский
Citations
0
American Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 10, 2025
Objectives: Non-Hodgkin lymphomas (NHL) are a diverse group of lymphoproliferative malignancies, often more unpredictable than Hodgkin lymphomas, with higher likelihood extranodal spread. NHL’s resistance to standard chemotherapy has increased, leading growing interest in personalized treatments like chimeric antigen receptor T-cell therapies (CAR-TCT). Methodology: A literature search was conducted across PubMed, ScienceDirect, Google Scholar, and the Cochrane Library for studies on CAR-TCT NHL treatment published until July 2024. The outcomes assessed included overall survival (OS), event-free (EFS), progression-free (PFS), objective response rate (ORR), adverse events (AEs). Data were pooled using RevMan 5.41 Comprehensive Meta-analysis 3. Results: Out 532 articles, 8 met inclusion criteria. significantly improved OS (HR: 0.79; 95% CI: 0.63-1.00; P =0.05) PFS 0.46; 0.36-0.58; <0.00001) compared chemotherapy. However, EFS not different 0.54; 0.26-1.09; =0.09). About 76.6% patients responded CAR-TCT, but ORR similar between therapy (MD: 19.23%; −11.34% 49.80%; =0.22). Safety analysis found grade ≥3 AEs incidence comparable care. associated neutropenia risk lower thrombocytopenia, anemia, nausea risks. Conclusion: improves refractory does notably impact EFS. While its is chemotherapy, better safety profile, making it promising option.
Language: Английский
Citations
0
Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(4), P. e010709 - e010709
Published: April 1, 2025
Background Chimeric antigen receptor (CAR) T-cell therapy depends on T cells that are genetically modified to recognize and attack cancer cells. Their effectiveness thus hinges the functionality of a patient’s own Since CAR is currently only approved for advanced cancers after at least one line chemotherapy, we evaluated potential negative effects prior exposure chemotherapy functionality. Methods We studied two B-cell non-Hodgkin’s lymphoma patient cohorts, collected before treatment (pre-therapy) other or more (median 3) lines (post-therapy). Leveraging multiparameter flow cytometry, single-cell RNA sequencing (scRNA-seq), whole-genome DNA methylation arrays in vitro testing generated cells, compared samples their suitability effective therapy. Results discovered significant modifications subsets transcriptional profiles secondary exposure. Our analysis revealed discernible shift towards phenotypically differentiated an upregulation markers indicative exhaustion. Additionally, scRNA-seq analyses gene expression epigenetic changes associated with diminished post-therapy Cytotoxicity assays demonstrated superior killing efficacy derived from treatment-naïve patients those history. Conclusions These findings corroborate employing frontline could enhance improve outcomes.
Language: Английский
Citations
0
Cancer Science, Journal Year: 2024, Volume and Issue: 115(11), P. 3532 - 3542
Published: Aug. 21, 2024
Abstract With recent advances in tumor immunotherapy, chimeric antigen receptor T (CAR‐T) cell therapy has achieved unprecedented success several hematologic tumors, significantly improving patient prognosis. However, solid the efficacy of CAR‐T is limited because high uncertainty and extremely restrictive microenvironment (TME). This challenge led to exploration new targets, among which fibroblast activation protein (FAP) gained attention for its relatively stable specific expression TME various making it a potential target therapy. study comprehensively analyzed biological characteristics FAP discussed application therapy, including theoretical basis, preclinical clinical research progress targeting with treatment. The challenges future optimization directions this treatment strategy were also explored, providing perspectives strategies tumors.
Language: Английский
Citations
2
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Aug. 29, 2024
Chimeric antigen receptor T cell (CAR-T) is a promising treatment for aggressive Non-Hodgkin lymphoma (NHL). The aim of the meta-analysis was to determine association between metabolic tumor volumes (MTV) derived on positron emission tomography before CAR-T infusion and survival patients with NHL.
Language: Английский
Citations
0
Computers in Biology and Medicine, Journal Year: 2024, Volume and Issue: 185, P. 109497 - 109497
Published: Dec. 13, 2024
Language: Английский
Citations
0